Circulatory levels of HsCRP in non-alcoholic fatty liver disease

 

 

REFERENCES

1. Angulo P., Lindor K.D. Non-alcoholic fatty liver disease (2001). J. Gastroenterol. Hepatol;17:S186–S190.
2. Mavrogiannaki AN, Migdalis IN. Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data (2013). Int J Endocrinol. 2013:450639.
3. Vikram NK, Misra A, Dwivedi M, Sharma R, Pandey RM, et al. (2003) Correlations of C-reactive protein levels with anthropometric profile, percentage of body fat and lipids in healthy adolescents and young adults in urban North India. Atherosclerosis168: 305–13.
4. Blake GJ, Ridker PM (2002) Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med252: 283–94.
5. Tarantino G, Conca P, Pasanisi F, et al. could  inflammatory markers help diagnose nonalcoholic steatohepatitis (2009) Eur J Gastroenterol Hepatol.;21:504–11.
6. Vidhate DA, Thomas J and Gupte A M. IL-6: An important mediator of obesity based inflammation (2013). International Journal of Advanced and Innovative Research 2013; 2: 9: 283-286.
7. Vidhate D A, Thomas J and Gupte A M.(2013) Association of IL-6 with Diabetes Mellitus in Indian Population from Navi Mumbai. International Journal of Recent Trends in Science and Technology, 8: 2: 100-102.
8. Deepali Vidhate, James Thomas, Becky Thomas, Simran Dhadiala, Arpit Murarka. Association of high sensitivity C – reactive protein (hs-CRP) with unstable angina:An alarm for vulnerable plaques in CAD patients (2018). International Journal of Clinical Biochemistry and Research, July-September ;5(3):458-463.
9. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology37: 917–23.
10. Yoneda M, Mawatari H, Fujita K, Iida H, Yonemitsu K, et al. (2007) High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol42: 573–82.
11. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, et al. (2009) Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int29: 82–8.
12. Kao PC, Shiesh SC, Wu TJ (2006) Serum C-reactive protein as a marker for wellness assessment. Ann Clin Lab Sci36: 163–9.
13. Duvnjak M, Lerotic I, Barsic N, Tomasic V, VirovicJukic L, et al. (2007) Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 13: 4539–50.
14. Crespo J, Cayon A, Fernandez-Gil P, Hernandez-Guerra M, Mayorga M, et al. (2001) Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology 34: 1158–63.
15. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, et al. (2005) Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117–21. 
16. Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, et al. (2004) Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology 40: 185–94.
17. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, et al. (2008) Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 103: 1372–9